In the fourth quarter, Kyverna achieved significant milestones, including the successful completion of the KYSA-8 registrational Phase 2 clinical trial for SPS, which demonstrated statistically significant clinical benefits across all primary and secondary endpoints. The company plans to submit its BLA in the first half of 2026, with a launch anticipated by year-end 2026. Additionally, the company is progressing its Phase 3 trial for gMG, with the first patient enrolled in December 2025.
Kyverna's CEO, Warner Biddle, emphasized the company's commitment to addressing unmet medical needs in autoimmune diseases, highlighting the potential of miv-cel (mivocabtagene autoleucel) to transform treatment paradigms. The company is also exploring additional indications, including progressive multiple sclerosis and rheumatoid arthritis, with promising data from ongoing trials.
The financial results showed a net loss of $37.8 million for the fourth quarter and $161.3 million for the full year, compared to $37.5 million and $127.5 million in the previous year. Research and development expenses were $30 million for the fourth quarter, reflecting a slight decrease from the prior year, while general and administrative expenses increased to $9.3 million.
Kyverna's strategic focus on advancing its CAR T therapies, coupled with a strong financial position, positions the company well for future growth and innovation in the biopharmaceutical sector.
